As I’ve written before, my business is evolving as the patient movement matures. For years our movement was, frankly, a question: “Should medicine listen to patients? Why?” I’ve spoken at hundreds of events, and happily, it’s no longer a question: we won. Now my speeches are increasingly about the academic and commercial aspects of patient engagement, not the “why.”
A sure sign of progress is that now the patient movement is progressing into business, which has opened the door for advisory work. My newest client is Massive Bio, a very different kind of entrant in the so-called “second opinion market,” where patients in trouble seek other options. It’s a popular idea but doing it successfully is not easy. Here’s the first post I wrote for their site; more will follow.
[Read more…]
